

Intelligence enabling the right drug at the right price

PRESENTED TO

# Township of Union BOE



## **Proprietary and Confidential**

PROPERTY OF REMEDY ANALYTICS

This document contains proprietary and confidential information that is protected by laws pertaining to such material. This document, the information in this document, and all rights thereto are the sole and exclusive property of Remedy Analytics and are intended for use by prospective clients, clients, approved partners, and employees of Remedy Analytics, and they may not be copied, used, or disclosed to anyone else, in whole or part, without the express written permission of Remedy Analytics.

Unless otherwise stated, the product names and acronyms used herein are trademarks, service marks, and registered trademarks of Remedy Analytics used under license. All other products names used herein are trademarks of their respective owners.



# PharmaLogic® PBM Discount Analysis Township of Union BOE

Major Price Component	CURRENT CONTRACT FINANCIALS	ACTUAL PERFORMANCE	PHARMALOGIC® RESULTS
Retail Brand Discount	20.00%	• 19.55%	19.25%
Retail Brand Dispensing Fee	\$0.45	• \$0.44	\$0.35
Retail Generic Discount	86.00%	• 77.74%	87.30%
Retail Generic Dispensing Fee	\$0.45	• \$0.49	\$0.35
Mail Brand Discount	21.50%	• 21.05%	20.25%
Mail Generic Discount	89.00%	• 77.07%	91.80%
Specialty Discount	21.00%	• 18.48%	22.50%

- Current Contract Financials Using contract discounts from the PBM contract effective July 1st, 2024
- Actual Performance Calculated using claims data from July 2024 to December 2024

Under performing

Acceptable



## PharmaLogic® Savings Township of Union BOE

### **Current Pharmacy Spend**

Based on claims data provided

\$ 6.1 M




PharmaLogic® Savings Detail			
Major Price Component	1-Year Savings	3 -Years Savings	
Retail Brand	\$19,873	\$169,719	
Retail Generic	\$190,062	\$610,200	
Mail Brand	\$53,893	\$189,319	
Mail Generic	\$101,975	\$325,732	
Specialty	\$610,448	\$1,929,850	
<b>Total Savings</b>	\$1,031,465	\$3,390,462	
Savings as a percent of Spend	19.20%	18.53%	

#### **Considerations:**

- Baseline rebates Used 2024 rebate minimum guarantees from the contract effective July 2024.
- Used 2 Tier plan rebates and a formulary with exclusions for savings estimate
- Savings are estimated based on projected spend net of rebates

## **Typical PBM Report**

**Adherence** Overall MPR score by Top Therapy Classes



## remedy PharmaLogic® Actionboard

Non-Adherent patient Adherent and Non-Adherent drilldown by sub-class breakdown for Adherence more in-depth analysis **Medication Adherence** Remedy Demo Client Is your population taking medication as prescribed? Adherence Category # of Patients Measured Average Patient PDC Percentage of Non-Adherent Patients # of Non-Adherent Patients Adherence Anti-Inflammatory\* 76.5% Category from table to reflect patients for that 78.8% category in lower part of dashboard. Non-Adherent Patients by Class: Diabetes Lantus Class 30 (48,4% Patients 23 (33.8% Patients) Januvia Class 22 (33.3% Patients) Glipizide Class Prandin Class = 1 (50.0% Patients) Multiple Sclerosis\* Adherence Non-Adherence by Number of Medication Classes/Drugs Non-Adherence by Copay Quartile Breakdown # of Non-Adherent Percentage of Non-Adherent Patients Percentage of Non-Adherent Patients Average Patient Cost / Rx 47 / 110 75.8% 48 / 82 70.2% 53.7% 22 / 39 Diabetes

> Adherence by comorbidity

53.4%

62.1%

Non-Adherence by patient cost share

13 / 16

2/2

7/1/2019-6/30/2020

8/14 55 / 81


83 / 206

78 (41.1% Patients)

51.6%

## **Typical PBM Report**


**Adherence**Overall MPR score by Top Therapy Classes



## remedy PharmaLogic® Actionboard

Diabetes Drug Therapy
Adherence in-depth analysis


#### Adherence




 Adherence and polypharmacy impact  Detection of potential gaps in care for recommended therapy guidelines

## **Typical PBM Report**

Adherence
Overall MPR score by Top Therapy Classes



## remedy PharmaLogic® Actionboard





# Agnostic Analytics + Full-Service Support Savings, Improved Outcome Management, & Protection

## Structural Financial Savings

- Algorithmically model the PBM contract
- Dissect and analyze the PBM claims
- Implement the **blueprint** to correction

### **Actionable Analytics**

- · Medication-centric data
- Health plan integration
- Benefit-gap analysis
- Clinical analytics
- Adherence analytics
- Plan design
- Formulary

### PBM Management

- Negotiation
- Issue resolution management
- Contract implementation oversight
- Change management (if applicable)
- Financial reconciliation
- Auditing
- Vendor management support

### **Quantitative Market Analysis**

- Full-cycle RFP management
- Market checks
- Trend modelling

### **Unparalleled Client Experience**

- High-touch service including professional clinical support
- Access to our expert client engagement and actuarial team
- Quarterly/semi-annual briefings

#### **Industry Intelligence**

- · On-going client education
- Critical news updates
- Evolving pharmacy and PBM industry insight



## Legal Disclaimer

This document has been prepared in good faith on the basis of information provided to Remedy Analytics, without any independent verification. If the data, information, and observations received are inaccurate or incomplete, our review, analysis, and conclusions may likewise be inaccurate or incomplete. Our conclusions and recommendations are developed after careful analysis and reflect our best professional judgment.

Remedy Analytics' representatives may from time to time provide observations regarding certain tax and legal requirements including the requirements of federal and state health care reform legislation. These observations are based on our good-faith interpretation of laws and regulations currently in effect, and are not intended to be a substitute for legal or tax advice. Please contact your legal counsel and tax accountant for advice regarding legal and tax requirements.



## Intelligence enabling the right drug at the right price

### **Remedy Analytics**

10700 W. Research Drive

Suite 3

Wauwatosa, WI 53226

### **Sales Contact**

Chris Fallon

Senior Vice President, Strategic Partnerships

(917) 841-0361

chris.fallon @remedyanalytics.com